top of page
-post-ai-image-5863_edited.jpg

Discover a Breakthrough in Cancer Treatment: Is TIL Therapy Right for You?

SERVICES

WHAT IS TIL THERAPY?

​​​

​​Tumor-infiltrating lymphocyte (TIL) therapy is an innovative cancer treatment that harnesses your body’s immune system to combat cancer. This advanced cancer immunotherapy involves extracting TILs, special white blood cells, from your tumor. These cells naturally attack cancer cells but often need a boost to be effective. In TIL therapy, doctors grow millions of these cells in a laboratory. Once expanded, the TILs are infused back into your body to enhance your immune response against the cancer. This personalized cancer treatment has shown promising results, especially in patients with melanoma and other types of cancers.

​

By utilizing personalized cancer therapy, TIL Therapy provides a promising option for patients, especially those with advanced cancers resistant to traditional treatments.

​

​


 


​

    TIL THERAPY IS A FORM OF IMMUNOTHERAPY

 

Immunotherapy is a type of medical treatment that helps the body’s own immune system to fight off disease. It is based on the fundamentals of science, such as recognizing how the body’s natural defenses can be used to treat and prevent illnesses. Immunotherapy can be used to treat a variety of diseases, including cancer, allergies, and autoimmune disorders. It works by stimulating the body’s immune system to recognize and attack certain cells, while leaving healthy cells unharmed. This is achieved through the use of drugs, vaccines, and other therapeutic interventions. Immunotherapy is an important part of modern medicine and can be used to treat several conditions.

WHAT ARE TIL BENEFITS & CHALLENGES

BENEFITS

  • Personalized treatment: TILs come from your own tumor, so the cells are already trained to recognize your cancer.

  • Works when other treatments fail: TIL therapy has helped patients whose tumors did not respond to chemotherapy or some immunotherapies.

  • Potential for long-lasting response: Some patients experience durable tumor shrinkage that lasts months or years.

  • Targeted attack with fewer long-term effects: Because the therapy uses your own immune cells, it can be more precise than some standard treatments and may reduce damage to healthy tissues.

  • Advances and combinations improving results: Ongoing research (for example, pairing TILs with checkpoint inhibitors) is increasing the chance of success for more patients.

CHALLENGES

  • Requires a tumor sample (surgery): Doctors must remove a piece of the tumor to harvest TILs, which may not be possible for every patient.

  • Time to prepare cells: Growing and testing TILs in the lab usually takes several weeks — too slow for some rapidly progressing cancers.

  • Side effects and short-term risks: Preparatory chemotherapy and the immune reaction to TILs can cause fever, low blood counts, fatigue, and in rare cases serious immune reactions (e.g., cytokine release syndrome). Medical teams monitor and manage these closely.

  • Availability and cost: TIL therapy is offered at specialty centers and in trials; it can be expensive and may not be widely available in all regions.

  • Tumor complexity can limit effectiveness: Solid tumors can block immune cells or vary widely within the tumor, making it harder for TILs to find and destroy every cancer cell.

         TIL History

Discovery & Early Trials
1980s

Scientists found that immune cells called tumor-infiltrating lymphocytes (TILs) could be taken from tumors, grown in the lab, and reinfused to attack cancer.

Larger Studies & Durable Responses
2010s

Clinical studies showed TIL therapy could shrink tumors and produce long-lasting responses for some melanoma patients.

FDA Approval (Lifileucel / Amtagvi)
2024

The FDA approved lifileucel (Amtagvi), the first TIL product for unresectable or metastatic melanoma after prior PD‑1 therapy.

Technique Refinement
1990s–2000s

Labs improved TIL growth methods (using IL‑2 and better culture techniques), increasing cell yield and effectiveness.

First Phase III Randomized Trial
2022

The M14TIL phase III study showed TIL therapy improved progression-free survival compared to standard treatment in advanced melanoma.

Now — Expansion & Ongoing Research
2025

Researchers are testing TIL therapy in more solid tumors and combining it with checkpoint inhibitors to boost outcomes.

TREATMENT WITH TIL

  • Medical check & tumor removal (screening & biopsy / surgery)
    Your care team first checks your overall health and confirms TIL therapy is an option. A small piece of the tumor is removed during a biopsy or surgery so doctors can collect the T cells inside it.

  • Tumor tissue sent to the lab
    The tumor sample is sent to a specialized lab. Technicians isolate the tumor-infiltrating lymphocytes (TILs) and test them to see if they can recognize the patient’s cancer.

  • TIL selection and initial growth
    The lab selects the best TILs and begins to grow them. This step ensures the T cells are active against the tumor.

  • Rapid expansion (making billions of TILs)
    Using a controlled process (often called a rapid expansion protocol), the chosen TILs are multiplied to very large numbers in the lab. Interleukin-2 (IL-2), a growth protein, is used to help the cells expand. This lab phase usually takes 2–6 weeks.

  • Pre-infusion preparation (lymphodepletion)
    Just before the TIL infusion, you typically receive a short course of chemotherapy — and rarely radiation — to reduce some of your existing immune cells. This “clears space” so the new TILs can work better. Lymphodepletion usually takes a few days.

  • TIL infusion (the treatment day)
    The grown TILs are given back to you through an IV (like a blood transfusion). Doctors may give IL-2 after the infusion to help the TILs survive and stay active. The actual infusion is usually a single treatment day, but IL-2 and early monitoring may last longer.

  • Hospital monitoring and side-effect care
    You will be monitored closely in the hospital for several days to weeks for side effects. Common short-term issues include fever, low blood counts, and fatigue. Rare but serious reactions (e.g., strong immune responses) can occur and are treated in hospital.

  • Follow-up, imaging, and further care
    Over the next weeks and months you’ll have regular clinic visits and scans to see how the cancer responds. Some patients need further treatments or supportive care, depending on results and side effects.

​​

​

​

Gemini_Generated_Image_s8muffs8muffs8mu.png
TIL-Therapy-Attacking-Microscope (1)_edited.png

TIL TREATMENT OF SOLID TUMORS 

​​Why TIL therapy is promising for melanoma and other solid tumors
Melanoma has been the cancer where TIL therapy has shown the most consistent benefit so far. Because melanoma tumors often attract T cells naturally, doctors can often collect enough TILs to expand. Clinical studies show that a significant share of patients with advanced melanoma experience tumor shrinkage, and some reach complete remission (no detectable tumor). Researchers are now testing the approach in other solid tumors such as cervical, ovarian, lung, colorectal, pancreatic cancers, and mesothelioma.
 

How well does TIL therapy work?
 

Results vary by cancer type and patient group. For advanced melanoma, multiple clinical trials have shown meaningful response rates and some long-lasting remissions. In other cancers, early trials show encouraging responses in subsets of patients, but more research is needed to know who benefits most.
 

Solid tumors are generally more challenging to treat than blood cancers for several reasons:


• Immunosuppressive tumor microenvironment: Tumors can release proteins that “turn off” immune cells or attract cells that dampen immune response.
• Physical barriers: Dense scar-like tissue around the tumor (stroma) can block T cells from reaching tumor cells.
• Tumor diversity: Solid tumors often contain a mix of cells with different markers, making it harder for one T cell type to attack all tumor cells.
How doctors are trying to overcome these barriers
Researchers use several strategies to improve TIL therapy for solid tumors:
• Combining TILs with checkpoint inhibitors (drugs that release immune system “brakes”).
• Improving lab methods to produce stronger, more active T cells.
• Selecting patients whose tumors have the right features (enough TILs and helpful tumor markers).
• Testing combination approaches — for example, TILs plus targeted drugs or radiation to make tumors more visible to the immune system.
 

What to expect if you pursue TIL therapy
 

In general, patients undergo tumor collection surgery, a lab expansion period (weeks), a short course of lymphodepleting chemotherapy, then the TIL infusion and close monitoring. Hospitals watch for side effects such as low blood counts, fever, and in rare cases, strong immune reactions.
 

Who might be a good candidate?


• Advanced or metastatic solid tumor (melanoma is the best-studied example).
• A tumor that can be safely removed to harvest TILs.
• Not responded to standard treatments, or eligible for a clinical trial.
Practical considerations
• Timing: Growing cells takes a few weeks, so TIL therapy is better suited for patients whose cancer is not rapidly progressing during that time.
• Where it’s offered: TIL therapy is available at specialized cancer centers and through clinical trials. Ask your care team for centers that offer it.
• Costs & coverage: Insurance coverage is evolving; FDA-approved products for certain cancers may be covered, but patient costs can vary.
 

Questions to bring to your doctor


1. Am I a candidate for TIL therapy or a related clinical trial?
2. Can my tumor provide enough cells to grow TILs?
3. What side effects should I expect and how are they managed?
4. How long will it take from surgery to infusion?
5. Where can I get this treatment and who will coordinate my care?
 

Next steps
 

If you’re interested in TIL therapy, ask your oncologist about eligibility and clinical trials. You can also contact specialized treatment centers that offer TIL programs. Use the contact form on this site to request information or to be connected with a specialist.
 

See the Sources section below for links to the research and trusted organizations behind this information.

​

Sources

​

​

​

​

​

​

​

​

​
 

 

 

​
 

CONTACT

GET IN TOUCH
 

If you or a loved one are exploring TIL Therapy and want to learn more, we’re here to help. Use the form below to ask questions, request more information, or understand whether Tumor-Infiltrating Lymphocyte (TIL) Therapy may be a treatment option worth discussing with your care team. While we do not provide medical advice, we aim to share clear, reliable information to help you make informed decisions about emerging cancer treatments.

Thanks for submitting!

bottom of page